JP2018527948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527948A5 JP2018527948A5 JP2018525528A JP2018525528A JP2018527948A5 JP 2018527948 A5 JP2018527948 A5 JP 2018527948A5 JP 2018525528 A JP2018525528 A JP 2018525528A JP 2018525528 A JP2018525528 A JP 2018525528A JP 2018527948 A5 JP2018527948 A5 JP 2018527948A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- adapter
- viral
- sequencing
- sequencing library
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012163 sequencing technique Methods 0.000 claims description 85
- 230000003612 virological effect Effects 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 46
- 239000002299 complementary DNA Substances 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 38
- 208000000474 Poliomyelitis Diseases 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 26
- 102000053602 DNA Human genes 0.000 claims description 22
- 241000991587 Enterovirus C Species 0.000 claims description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 12
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 12
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 108020000999 Viral RNA Proteins 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 238000007481 next generation sequencing Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims description 4
- 229940033330 HIV vaccine Drugs 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 241001493065 dsRNA viruses Species 0.000 claims description 2
- 229940124724 hepatitis-A vaccine Drugs 0.000 claims description 2
- 229940124737 hepatitis-C vaccine Drugs 0.000 claims description 2
- 229960003971 influenza vaccine Drugs 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000011176 pooling Methods 0.000 claims description 2
- 238000007480 sanger sequencing Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 229940124866 human papillomavirus vaccine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199663P | 2015-07-31 | 2015-07-31 | |
| US62/199,663 | 2015-07-31 | ||
| PCT/US2016/044788 WO2017023782A1 (en) | 2015-07-31 | 2016-07-29 | Methods of analyzing virus-derived therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527948A JP2018527948A (ja) | 2018-09-27 |
| JP2018527948A5 true JP2018527948A5 (enExample) | 2019-07-04 |
| JP6907202B2 JP6907202B2 (ja) | 2021-07-21 |
Family
ID=56682276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525528A Active JP6907202B2 (ja) | 2015-07-31 | 2016-07-29 | ウイルス由来の治療剤を解析する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10662464B2 (enExample) |
| EP (1) | EP3329013B1 (enExample) |
| JP (1) | JP6907202B2 (enExample) |
| CN (2) | CN108026567B (enExample) |
| WO (1) | WO2017023782A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016201224A1 (en) | 2015-06-10 | 2016-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Processes for production and purification of nucleic acid-containing compositions |
| CN109280700B (zh) * | 2018-09-17 | 2022-04-12 | 上海海洋大学 | 精确测定中华绒螯蟹线粒体全基因组序列的方法 |
| CN110923359A (zh) * | 2019-11-29 | 2020-03-27 | 中国食品药品检定研究院 | 检测ⅰ型脊灰减毒活疫苗核酸突变的质谱检测引物组及其方法 |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2021243333A2 (en) * | 2020-05-29 | 2021-12-02 | Biohsv Holdings, Inc. | Mass nucleic acid testing |
| CN114067907B (zh) * | 2020-07-31 | 2022-07-08 | 普瑞基准生物医药(苏州)有限公司 | 一种准确鉴定rna病毒基因组变异的方法 |
| CN114075596A (zh) * | 2020-08-12 | 2022-02-22 | 深圳华大因源医药科技有限公司 | 一种基于高通量测序技术检测目的微生物基因组rna的方法 |
| CN112646859B (zh) * | 2020-12-30 | 2022-04-26 | 中国人民解放军疾病预防控制中心 | 一种基于宏基因组学的呼吸道咽拭子样本的建库方法和病原检测方法 |
| CN113722162B (zh) * | 2021-08-17 | 2025-02-14 | 大连海天兴业科技有限公司 | Mvb网卡稳定性测试系统、方法及存储介质 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728519A (en) * | 1990-11-06 | 1998-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Assay for virulent revertants of attenuated live vaccines and kits therefor |
| CA2268737A1 (en) * | 1997-08-07 | 1999-02-18 | Altwell Biotech. Inc. | Replication-competent recombinant sabin type 1 strain of poliovirus |
| WO2009091934A1 (en) | 2008-01-17 | 2009-07-23 | Sequenom, Inc. | Single molecule nucleic acid sequence analysis processes and compositions |
| US8066983B2 (en) * | 2008-03-14 | 2011-11-29 | The Research Foundation Of State University Of New York | Attenuated poliovirus |
| GB201213770D0 (en) | 2012-08-02 | 2012-09-12 | Ucl Business Plc | Screening methods |
| ES2688653T3 (es) * | 2012-11-21 | 2018-11-06 | Duke University | Poliovirus oncolítico para tumores humanos |
| WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
| WO2016201224A1 (en) | 2015-06-10 | 2016-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Processes for production and purification of nucleic acid-containing compositions |
-
2016
- 2016-07-29 WO PCT/US2016/044788 patent/WO2017023782A1/en not_active Ceased
- 2016-07-29 US US15/580,299 patent/US10662464B2/en active Active
- 2016-07-29 EP EP16750580.9A patent/EP3329013B1/en active Active
- 2016-07-29 CN CN201680045182.1A patent/CN108026567B/zh active Active
- 2016-07-29 JP JP2018525528A patent/JP6907202B2/ja active Active
- 2016-07-29 CN CN202111246733.XA patent/CN114107559A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527948A5 (enExample) | ||
| ES2990227T3 (es) | Composiciones y procedimientos de análisis de ácido nucleico de secuencia única | |
| CN101965410B (zh) | 用于产生可测序文库的改进的核酸处理的系统和方法 | |
| EP3561159B1 (en) | High-throughput single cell barcoding | |
| JP6847499B2 (ja) | 環状コンセンサスシークエンシングのための一本鎖環状ｄｎａライブラリー | |
| JP6430631B2 (ja) | リンカー要素、及び、それを使用してシーケンシングライブラリーを構築する方法 | |
| JP2017519774A5 (enExample) | ||
| WO2017040316A1 (en) | Sample analysis, presence determination of a target sequence | |
| AU2016324473B2 (en) | Virome capture sequencing platform, methods of designing and constructing and methods of using | |
| JP2013529472A5 (enExample) | ||
| JP6907202B2 (ja) | ウイルス由来の治療剤を解析する方法 | |
| JP7539770B2 (ja) | ゲノム再編成検出のための配列決定方法 | |
| KR20180052317A (ko) | 메르스 코로나바이러스 검출용 프라이머 세트 및 이의 용도 | |
| JP2019022503A (ja) | Ｐｅｇを介した核酸分子のアセンブリ | |
| JP2019504624A (ja) | 核酸配列決定のための新規アダプターおよび使用法 | |
| Lin et al. | Next-generation sequencing and bioinformatic approaches to detect and analyze influenza virus in ferrets | |
| US10385391B2 (en) | Entangled mate sequencing | |
| WO2017021752A1 (en) | Methods for amplifying and sequencing the genome of a hepatitis c virus | |
| JP2024522025A (ja) | 核酸特性評価のための増幅手法 | |
| US20230129100A1 (en) | Detection of low abundance nucleic acids | |
| WO2021202344A2 (en) | Detection of low abundance viruses | |
| US20200208140A1 (en) | Methods of making and using tandem, twin barcode molecules | |
| Zmienko et al. | Transcriptome sequencing: next generation approach to RNA functional analysis | |
| CN119082272A (zh) | 基于工程化Cas12b及sgRNA骨架的核酸检测方法 | |
| CZ33796U1 (cs) | Primery pro sekvenaci části genomu viru šarky švestky za účelem stanovení kmenu viru a jeho případných mutací |